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Differentially methylated CpGs in response
to growth hormone administration in children
with idiopathic short stature
Xiaojian Shao1* , Catherine Le Stunff2, Warren Cheung3, Tony Kwan4, Mark Lathrop4, Tomi Pastinen3* and
Pierre Bougnères2*

Abstract
Background: Recombinant human growth hormone (rhGH) has shown a great growth-promoting potential in
children with idiopathic short stature (ISS). However, the response to rhGH differs across individuals, largely due to
genetic and epigenetic heterogeneity. Since epigenetic marks on the methylome can be dynamically influenced by
GH, we performed a comprehensive pharmacoepigenomics analysis of DNA methylation changes associated with
long-term rhGH administration in children with ISS.
Results: We measured DNA methylation profiles before and after GH treatment (with a duration of ~ 18 months in
average) on 47 healthy children using customized methylC-seq capture sequencing. Their changes were compared
and associated with changes in plasma IGF1 by adjusting sex, age, treatment duration and estimated blood proportions. We observed a considerable inter-individual heterogeneity of DNA methylation changes responding to GH
treatment. We identified 267 response-associated differentially methylated cytosines (DMCs) that were enriched in
promoter regions, CpG islands and blood cell-type-specific regulatory elements. Furthermore, the genes associated
with these DMCs were enriched in the biology process of “cell development,” “neuron differentiation” and “developmental growth,” and in the TGF-beta signaling pathway, PPAR Alpha pathway, endoderm differentiation pathway,
adipocytokine signaling pathway as well as PI3K-Akt signaling pathway, and cAMP signaling pathway.
Conclusion: Our study provides a first insight in DNA methylation changes associated with rhGH administration,
which may help understand mechanisms of epigenetic regulation on GH-responsive genes.
Keywords: Pharmacoepigenomics, Growth hormone, DNA methylation, Intervention epigenetics, Idiopathic short
stature
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Introduction
Growth hormone (GH) acts directly on intracellular pathways downstream of the GH receptor or via
the stimulation and action of IGF1 [1]. Physiological
effects of GH are mainly on growth, body composition
and metabolism. In the epiphyseal growth plate, GH
effects are largely mediated by promoting IGF1 production to stimulate skeletal growth. In addition, GH
is known to increase muscle mass. GH also contributes
to the acute metabolic response to stressful situations,
such as fasting [2, 3], exercise [4], injuries, critical
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illnesses [5] and infectious diseases [6] by acting on
the liver, pancreatic beta cells, adipose tissue and muscle. Overall, most of these GH effects are mediated by
activating the transcription of numerous genes.
Non-physiological exposure to GH occurs in the
human clinic when children with short stature (SS)
receive supra-physiological doses of recombinant
human GH (rhGH) to stimulate their skeletal growth.
These cases differ widely in the level and duration of
exposure to rhGH which may leave lasting marks in
different tissues that could conceivably be based on
epigenetic mechanisms.
Changes in CpG methylation of the genome are one
of the most studied epigenetic mechanisms. They can
facilitate or reduce the transcription of certain genes
when they occur in the regulatory zones of these
genes. Once installed, some of them cannot be erased.
However, they can show a certain plasticity and vary
with age or environmental factors [7–11]. Most of
them are variable depending on the tissue [12–14].
Modifications of CpG methylation have been associated with cancer, metabolic and cardiovascular diseases [15–17]. Following binding to its receptor, GH
activates GHR-associated Src family kinases, acting via
other intracellular pathways [18], such as ERK and Jun,
which are known to affect CpG methylation [19].
It was therefore interesting to investigate whether
GH was capable of producing its own epigenetic marks
on the methylome. The only opportunity to detect
them in the human clinic is to study the methylome
before and after exposure to the hormone. This is made
possible in one particular circumstance, the application of rhGH treatment to normal small children.
Given the considerable individual variability of methylation marks, it would have been difficult to compare
rhGH treated with untreated children. Therefore, we
searched for acquired CpG modifications by studying
the same children before and during rhGH exposure.
As for most DNA methylation studies in humans, it
was only possible to study blood cells in these children, with the expectation that changes in blood cells
may reflect those occurring in the physiological target
tissues of GH action. It is probably important to clarify
that our study does not address at all the epigenetic
variations that could contribute to the mechanisms of
short stature, which have been the subject of a number of previous studies. Such methylation marks are
not expected to vary upon GH administration and are
therefore outside the scope of our approach devoted to
the epigenetic consequences of exposure to GH action.
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Methods
Cohort—sample collection

DNA samples were obtained from 47 children with nonpathological idiopathic short stature (ISS) recruited
among 317 children who served as controls in a study
of type 1 diabetes (T1D) epigenetics [20]. The 47 studied children with short stature all had ISS, as defined
[21]. Briefly, this diagnosis requires that child’s height
is < − 2SD (standard deviation) from the population average, with a birth length > − 2SD for gestational age (none
of them had intrauterine growth retardation) and appropriate for parents’ height, then linear and normal growth
rate, and no detectable etiology for the short stature, such
as chromosomal, endocrine, or skeletal diseases. Classically, testing of such short children includes clinical
examination, bone X-rays, IGF1measurement and/or GH
stimulation tests (to exclude GH deficiency). The 47 studied children all went through these screening analyses,
and none of them showed any abnormality in the cited
parameters. This study was supported by the Programme
Hospitalier de Recherche Clinique of the French Ministry
of Health according to the French bioethics law with the
objective of studying gene–environment factors in young
patients with T1D and age-matched controls. Families
were carefully informed about the investigational nature
of the study and signed an informed consent agreed by
CPP (number DC-2008-693; NI 2620, Comité de Protection des Personnes). The studied children had received
rhGH treatment for a duration of 6–38.4 months.
None had deficiencies of GH or other hormones, chromosomal disorders or syndromes, skeletal dysplasia or
metabolic disease. All children received rhGH as daily sc
injections 6 days/wk, starting with a 40 µg/kg day rhGH
dose and following a target-to-treat rhGH dosing protocol based on the growth response to treatment, so that
individual average dose ranged 40–113 µg/kg day across
the studied children. Children gave two blood samples,
one before onset of rhGH treatment and the other after
6–38.4 months of rhGH treatment. All were seen as outpatients every 6 months for clinical examination and
measurements of serum IGF-I. Children were healthy at
time of study, with no sign of viral or other intercurrent
infection. Blood samples were collected in the course of
routine medical evaluation of patients. DNA methylation was measured in peripheral blood mononuclear cells
(PBMC) samples from these patients before and during
treatment.
Isolation of genomic DNA

Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood using a density gradient. Five
milliliters of fresh blood were mixed with 5 ml of NaCl
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154 mM, and 5 ml of Lymphoprep solution (Eurobio,
Paris, France) was added to the diluted blood and centrifuged for 20 min at room temperature at 800 g. After
centrifugation, the interphase containing PBMC was
carefully aspirated and the cells were mixed with NaCl.
The cell suspension was centrifuged at 300 g and the cell
pellet washed with PBS. PBMC were frozen at − 80 °C.
Nucleic acids were extracted from PBMC using Gentra
Puregene blood kit (Qiagen, Hilden, Germany).
Measurement of IGF1 concentrations

IGF1 concentrations were measured in serum samples
around 07.00 am to 08.00 pm before breakfast using a
chemiluminescent immunometric assay after pre-treatment with acid using Immulite®2000 (Siemens Healthcare Diagnostics Products Llanberis, UK). IGF1 values
under treatment were averaged for analysis.
DNA methylation capture sequencing

Methylation capture sequencing (MCC-Seq) was performed as previously described [22–24]. In brief, the
MCC-Seq protocol was carried out using the SeqCap
Epi Enrichment System protocol (Roche NimbleGen)
[22–24]. Specifically, a whole-genome sequencing library
was prepared and bisulfite converted, amplified and then
a capture enriching for targeted bisulfite-converted DNA
fragments was carried out. Equal amounts of multiplexed
libraries (12 samples per capture) were combined and
were further amplified. Lastly, the MCC-Seq libraries
were sequenced on the Illumina HiSeq4000 or NovaSeq
6000 system using 100 bp paired-end sequencing. More
specifically, whole-genome sequencing libraries were
generated from 700 to 1000 ng of genomic DNA spiked
with 0.1% (w/w) unmethylated λ DNA (Promega) previously fragmented to 300–400 bp peak sizes using the
Covaris focused-ultrasonicator E210. Fragment size was
controlled on a Bioanalyzer DNA 1000 Chip (Agilent),
and the KAPA High Throughput Library Preparation Kit
(KAPA Biosystems) was applied. End repair of the generated dsDNA with 3′- or 5′-overhangs, adenylation of
3′-ends, adaptor ligation and clean-up steps were carried out as per KAPA Biosystems’ recommendations.
The cleaned-up ligation product was then analyzed on
a Bioanalyzer High Sensitivity DNA Chip (Agilent) and
quantified by PicoGreen (Life Technologies). Samples
were then bisulfite converted using the Epitect Fast DNA
Bisulfite Kit (Qiagen), according to the manufacturer’s
protocol. Bisulfite-converted DNA was quantified using
OliGreen (Life Technologies) and, based on quantity,
amplified by 9–12 cycles of PCR using the Kapa Hifi
Uracil + DNA polymerase (KAPA Biosystems), according to the manufacturer’s protocol. The amplified libraries were purified using Ampure Beads and validated on
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Bioanalyzer High Sensitivity DNA Chips, and quantified
by PicoGreen.
The hybridization procedure of the amplified bisulfiteconverted library was performed as described by the
manufacturer, using 1 μg of total input of library, which
was evenly divided by the libraries to be multiplexed, and
incubated at 47 °C for 72 h. Washing and recovering of
the captured library, as well as PCR amplification and
final purification, were carried out as recommended by
the manufacturer. Quality, concentration and size distribution of the captured library were determined by Bioanalyzer High Sensitivity DNA Chips.
This blood MCC-Seq panel covers (1) the majority
of human gene promoters, blood-cell-lineage-specific
enhancer regions and methylation footprint regions
[25] observed in blood, (2) CpGs from Illumina Human
Methylation 450 Bead Chips and (3) published autoimmune-related SNPs as well as SNPs in their LD regions
with r2 > 0.8. Overall, it covers 4,861,805 CpGs which
have been applied to multiple blood-based epigenomewide association studies [24, 26].
MCC‑Seq data process

Targeted MCC-Seq HiSeq and NovaSeq reads were
aligned using the Epigenome Pipeline available from the
DRAGEN Bio-IT platform (Edico Genomics/Illumina).
Specifically, the MCC-Seq paired-end raw reads were
first demultiplexed into FASTQ files using Illumina’s
bcl2Fastq2-2.19.1 software. Reads were then trimmed
for quality (phred33 ≥ 20) and Illumina adapters using
trimgalore v.0.4.2 (https://www.bioinformatics.babra
ham.ac.uk/projects/trim_galore/), a wrapper tool around
Cutadapt [27] and FastQC (https://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). Then, the trimmed
reads were aligned, per sequencing lane, to the bisulfiteconverted GRCh37 reference genome using DRAGEN
EP v2.6.3 or later in paired-end mode using the directional/Lister methylation protocol presets; alignments
were calculated for both strands, and the unique alignment with highest quality was retained. Lane bam files
were merged and then de-duplicated using Picard (version 2.9). A genome-wide cytosine methylation report
was generated by DRAGEN to record counts of methylated and unmethylated cytosines at each cytosine position in the genome. Methylation counts are provided for
the CpG, CHG and CHH cytosine contexts. DNA methylation level of each CpG was calculated by the number
of methylated reads over the total number of sequenced
reads. CpGs that were located within sex chromosomes,
overlapping with SNPs (dbSNP 137), the DAC Blacklisted Regions or Duke Excluded Regions (generated by
the ENCODE project) were removed. CpG sites with less
than 20X read coverage were also discarded.
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Variants/SNPs (including homozygous alternate and
heterozygous genotypes) were inferred using Bis-SNP
(version 0.82.2) [28] on the de-duplicated bam files.
The homozygous reference genotypes of individuals on
these SNPs were extracted from the aligned bam files by
requiring >  = 10X read coverage aligned to the reference
allele. Hierarchical clustering was performed based on
the genotype profiles of SNPs on chromosome 1 where
genotypes were inferred from all samples.
Statistical analysis

A linear regression model (LM) was built to investigate
the association between the changes of DNA methylation level before and after treatment (delta beta) and
the changes of IGF1 level (delta IGF1) by correcting age
onset, the treatment duration and the estimated blood
cell proportions. We used the R function lm() to fit the
model and calculated p values for variables of interest.
Due to limited sample size, the nominal p value < 1e−4
was used as a threshold of statistical significance to
determine differentially methylated CpGs (DMCs). To
reduce the impact of zero-inflated methylation differences on inferring the regression, we limited our analysis
on CpGs that have >  = 30% of pairs with nonzero methylation differences. Blood deconvolution was done using
constrained linear projection [29] via the projectMix
function of the RefFreeEWAS package, using a custom
panel of 30,455 cell-type-specific hypo-methylated and
hyper-methylated CpGs. The blood reference epigenome
profiles include neutrophil, monocyte, B cell and T cell.
Genome features and function enrichment analysis

We downloaded the genome feature annotation tables,
including transcription start sites (TSSs), 3’UTRs,
5’UTRs, first exons, exons, introns and transcription end
sites (TESs), from the UCSC genome browser with the
hg19 build version (https://genome.ucsc.edu/). We considered both TSS200 (200 bp from TSSs) and TSS1500
(1500 bp from TSSs) for the promoter regions. We also
downloaded the CpG islands (CGI) annotation table from
the UCSC genome browser. Furthermore, CGI north and
south shores were defined as the 2-kb flanking sequences
on upstream and downstream of CGIs, respectively, and
north and south shelves were defined as the 2-kb flanking
sequences beyond the shores. Genome feature enrichment analyses of GH response DMCs were performed
using Fisher’s exact test for significance where the background set was the all testable CpGs. The gene ontology
enrichment analyses were performed using homer [30]
(version 4.11) with gene sets detected from the immune
panel as the background set.
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Results
Descriptions of the GH cohort

Main characteristics of the 47 subjects (pairs) included in
this study are shown in Table 1. All had ISS as defined by
[31]. Briefly, ISS is a condition in which the height of the
individual is more than 2 standard deviations (SD) below
the corresponding mean height for a given age, sex and
population, in whom no identifiable disorder is present.
The sex-matched participants (24 females vs. 23 males)
were aged 4.9 to 13.1 years at time of starting rhGH treatment. They received a mean supra-physiological dose of
rhGH of 70.8 μg/kg per day for a duration range from 6 to
38.4 months. During rhGH therapy, the mean increase in
plasma IGF1 across children ranged from 4 to 658 ng/ml.
Differentially methylated CpGs in response to GH
treatment

The average sequence genome coverage in targeted
regions for these 94 samples was 25-fold (Additional
file 1: Table S1). Close to 5.3 million CpGs (including
those out of the targeted panels) were captured at autosomes with more than 20-fold read coverage and in at
least one sample. When restricting attention to CpGs
with good sample coverage in at least 10 before and after
treatment pairs, 3,342,494 CpGs at autosomes remained
for downstream analysis. In addition, the paired samples before and after GH treatment for 47 children were
clustered well according to their genotype profiles which
were inferred from the methylation sequencing data
(Additional file 2: Figure S1).
We first compared the DNA methylation difference
of each CpG per individual pair. For these ~ 3.3 M CpGs
across 47 individual pairs, 68.1% of all comparisons
were measured, see the sample (pair) coverage distribution of CpGs in Additional file 3: Figure S2A. A majority of the CpGs showed low mean absolute methylation

Table 1 Main characteristics of the studied children
Mean ± SD
N

47

Sex (M/F)

23/24

Age at rhGH onset (year)

9.8 ± 1.8

Tanner stage (stage 0/stage 1)
Mean rhGH dose (µg/kg day)
Treatment duration (months)
Growth rate before treatment (cm/year)
Growth rate during treatment (cm/year)
Plasma IGF1 at baseline (ng/ml)
Mean IGF1during treatment (ng/ml)
Delta IGF1 under treatment (ng/ml)

36/11

70.8 ± 19

18.1 ± 7.3
4.6 ± 1.0

9.1 ± 1.5

167 ± 80

402 ± 123
235 ± 117
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difference (e.g., > 95% of these CpGs are showing mean
methylation differences ≤ 5%) and low standard deviation
(Fig. 1A, B). Specifically, it showed majority of them have
DNA methylation difference of zero as indicated in the
middle peak of Fig. 1A. Meanwhile, it also showed two
lower sub-peaks which indicated the potential epigenetic
responses to the GH treatment and represent the average methylation changes (i.e., ~  ± 5%). When considering each of the measured CpG pairs across 47 children
(n = 107,019,585), the mean absolute value of the methylation changes between the baseline and rhGH stimulated
samples is 4.8 ± 6.6% (SD). There is no difference between
male and female groups (Additional file 3: Figure S2B).
By requiring ≥ 10% methylation difference between the
baseline and rhGH stimulated samples, 304,528 CpGs
showed either ≥ 10 hypo-methylated samples or ≥ 10
hyper-methylated samples. Among those CpGs, 37,128
CpGs showed discordant responses to rhGH treatment
(i.e., ≥ 10 hypo-methylated samples and ≥ 10 hypermethylated samples). Furthermore, the corresponded
numbers of CpGs drop to 11,398 and 0 if requiring ≥ 20%
methylation changes. Overall, we observed quite heterogeneous DNA methylation responses to rhGH treatment. Additional file 3: Figure S2C demonstrates the
methylation changes pattern for the top 5% most variable
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CpGs whose methylation profiles were measured for all
individuals.
We observed that roughly 14.64%, 3.76% and 1.07% of
the CpGs showed methylation difference > 10%, 20% and
30% comparing the baseline and after treatment samples, respectively (Fig. 1C). We then correlated the ratio
of CpGs showing methylation difference > 10% of individuals with other phenotypes such as onsite age, difference of blood proportions and changes in plasma IGF1
concentration under treatment. We observed that the
proportion changes of T cell and neutrophil are significantly corrected with the ratio of CpGs showing >  = 10%
differences (r = 0.39 and − 0.32, with p = 0.006 and 0.03,
respectively) (Fig. 1D, E), but not for others parameters. This correlation trends are further increased when
checking the ratio of CpGs showing >  = 20% or 30%
methylation level changes (Additional file 1: Table S2).
Furthermore, we also observed that the proportion
changes of B cell are showing significant correlation with
the ratio CpGs showing 30% methylation level changes.
Additional file 1: Table S2 presents the detailed correlations between CpG ratios at different levels of methylation changes and various phenotypic features. This
implied that the methylation level changes might be confounded by the blood proportions changes.

Fig. 1 Characterization of DNA methylation changes before and after GH stimulation treatment. A The distribution of the DNA methylation
changes. B The scatter plot between the DNA methylation changes and standard deviation of DNA methylation changes over all CpGs. The density
of CpGs was also illustrated using different colors as indicated in the legend. C The distribution of the percentage of CpGs showing different level
of differential methylation changes (> 10%, > 20% and > 30%) across samples. D, E The correlation between the percentage of DMCs (at > 10%
methylation level difference) and the changes of T cell proportion (D) and neutrophil proportion (E). The sex and treatment duration were indicated
with different colors and different sizes of the dots
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To identify the differentially methylated CpGs upon
long-term exposure to rhGH, we fit a linear regression
model on the difference between the DNA methylation
values of all baseline and post-treatment PBMC samples and the difference in IGF1 values (Delta-IGF1)
by adjusting the age at onset of treatment, treatment
duration and differences in blood cell proportions
before and after treatment. Figure 2A, B illustrates the
QQ-plot and the Manhattan plot for this analysis. We
did not observe any significant associations between
Delta-IGF1 and the methylation level changes of CpGs
(response DMCs) between baseline and post-treatment
samples after multiple test corrections at a FDR of 0.05.
However, we identified 2599 CpGs showing response
DMCs (p < 1e−3) among baseline and post-treatment
samples where 1317 response DMCs are negatively
correlated and 1282 DMCs are positively correlated.
With a more stringent p value threshold, we identified
267 DMCs at p value < 1e−4 with 123 negatively correlated and 144 positively correlated response DMCs.
The DNA methylation change’s pattern of the DMCs
at p < 1e−3, which were also measured by all the individuals, is illustrated in Fig. 2C. Table 2 lists the top
20 significant response DMCs with the top examples
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demonstrated in Fig. 2D–G, and Additional file 1:
Table S3 lists the full list of these 267 response DMCs.
Genome feature and function enrichment analysis
of response DMCs

We first performed a genomic feature enrichment analysis of response DMCs with the p value < 1e−4 and p
value < 1e−3. We observed that the response DMCs with
p value < 1e−3 were slightly enriched in the first exon,
TES200 and CGIs (Fig. 3A) but no significant regions
for the response DMCs with p value < 1e−4 (Fig. 3A).
Furthermore, we also observed slightly enrichments on
the blood-specific regulatory elements—DNase I hypersensitive sites (DHSs) regions of CD19 and CD20 for
the response DMCs with p value < 1e−4 but not for the
response DMCs with p value < 1e−3 (Fig. 3A).
We then performed a gene function enrichment
analysis on 265 genes which are associated with 267 p
value < 1e−4 response DMCs using Homer (annotatepeaks function) [30]. It revealed that these genes were
enriched in the Biological process GO term of “neuron differentiation” (p value < 1e−05), “cell development” and “cell morphogenesis” (p value < 1e−4), as
well as other developmental process-related terms,

Fig. 2 The distribution of response-dependent differentially methylated CpGs. A The QQ-plot of p values from the analysis of the CpGs respond to
the GH treatment. B Manhattan plot of p values from the response analysis. C The heatmap of response DMCs at p value < 1e−3 whose methylation
profiles were measured for all individuals. Different phenotype features (including different sequencing platforms, sex, puberty, age onset,
treatment duration, changes of IGF1 concentration and GH dose) are illustrated in the top plots. D–G Scatter plot for the examples of top response
DMCs. The sex and treatment duration were indicated with different colors and different sizes of the dots
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Table 2 The top 20 response DMCs list with p value < 1e−4. The response DMCs were sorted by the p value. CpG chromosome and
position, regression p value, beta value (coefficient) and the annotated closest gene information (including genomic Annotation,
Distance to TSS, Gene Name, Gene Type, and Gene Description of the closest gene) were provided
chr.position

p value

chr18.48723610

3.49E−08 − 0.22733 exon (NM_016626, exon
1 of 2)

chr1.150532375

7.49E−07 − 0.39527 TTS (NR_104133)

chr10.105647890 1.17E−06

Beta

Annotation

Distance to TSS Gene Name Gene type

0.893509 intron (NM_024928, intron
9 of 9)

440
7971

MEX3C

Gene description

Protein-coding mex-3 RNA binding family
member C

MIR4257

ncRNA

30,051

STN1

Protein-coding STN1 subunit of CST complex

microRNA 4257

chr11.10679586

1.56E−06 − 0.58556 intron (NM_001206880,
intron 1 of 19)

− 5739

MRVI1

Protein-coding Murine retrovirus integration
site 1 homolog

chr3.156848563

1.97E−06 − 0.14999 Intergenic

− 7773

LINC00880

ncRNA

chr12.129252225 2.68E−06 − 1.11703 Intergenic

56,277

SLC15A4

Protein-coding Solute carrier family 15
member 4

54,958

chr1.50834156

3.76E−06

DMRTA2

Protein-coding DMRT-like family A2

chr16.56553641

3.90E−06 − 0.13719 intron (NM_031885, intron
1 of 16)

294

BBS2

Protein-coding Bardet-Biedl syndrome 2

chr6.99283220

3.95E−06 − 0.12451 exon (NM_005604, exon
1 of 1)

771

POU3F2

Protein-coding POU class 3 homeobox 2

chr22.46519089

0.153745 Intergenic

Long intergenic non-proteincoding RNA 880

MIRLET7B

ncRNA

microRNA let-7b

chr1.25228801

4.78E−06 − 0.30407 exon (NM_004350, exon
5 of 5)

4.61E−06 − 1.1146

Intergenic

17,105

MIR6731

ncRNA

microRNA 6731

chr2.241976241

4.88E−06 − 0.48453 exon (NM_001080437,
exon 5 of 32)

38,207

SNED1

Protein-coding Sushi, nidogen and EGF-like
domains 1

chr7.139187227

5.05E−06 − 0.39751 Intergenic

− 18,809

KLRG2

Protein-coding Killer cell lectin-like receptor
G2

chr4.79545349

5.32E−06

0.366908 Intergenic

− 21,798

LINC01094

ncRNA

chr16.66554996

5.35E−06

0.684785 intron (NR_073520, intron
5 of 8)

29,028

TK2

Protein-coding Thymidine kinase 2

chr11.68608981

5.63E−06 − 0.13725 intron (NM_001876, intron
1 of 18)

402

CPT1A

Protein-coding Carnitine palmitoyltransferase 1A

chr4.122871430

5.71E−06

1784

TRPC3

Protein-coding Transient receptor potential
cation channel subfamily C
member 3

0.274039 intron (NM_001366479,
intron 1 of 10)

chr11.8364991

6.74E−06

0.562738 Intergenic

chr9.117026652

6.75E−06

1.475667 exon (NM_032888, exon
29 of 61)

chr3.183873096

6.93E−06

0.345301 promoter-TSS
(NM_004423)

including the “Development growth” and “Growth”
terms (p value < 3e−3) (Fig. 3B). Strikingly, these genes
were observed to be enriched in the “Endoderm differentiation pathway” (p value < 1e−3), “Adipocytokine
signaling pathway” (p value = 0.019), “TGF-beta signaling pathway” (p value = 0.02) and “PPAR Alpha pathway” (p value < 0.03) as well as other pathways related
to growth factor receptor or stimulating hormone signaling pathway (Fig. 3C). Furthermore, the common
domain families of “Rnase H1,” “WH/WH-like DNA” (p
value < 1e−4), “TIMP,” “PWWP,” etc. (p value < 1e−3),
were observed to be over-represented in the proteins
of these response DMCs-associated genes (Fig. 3D). In

9524

− 74,658
54,939
− 68

Long intergenic non-proteincoding RNA 1094

LMO1

Protein-coding LIM domain only 1

MIR455

ncRNA

DVL3

Protein-coding Disheveled segment polarity
protein 3

microRNA 455

addition, when exploring the enrichment for genes associated with response DMCs at p < 1e−3 (n = 2247 genes),
we observed that these genes were enriched in “PI3K-Akt
signaling pathway,” “Sphingolipid signaling pathway” and
“cAMP signaling pathway” (Additional file 4: Figure S3).
We compared our identified DMCs with previously
reported GH-related DMCs (n = 239, [32]). We did not
find that any reported significant DMCs were replicated
at our study, but when expanded to 1 kb distance-based
neighboring CpGs, we observed a slight enrichment
(fold-change of 1.73) of these reported DMCs at our
response DMCs (p value < 0.001) compared with our
non-significant CpGs (p value > 0.001) although this
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Fig. 3 Genome feature and functional enrichment analysis of the response DMCs. A Genomic features and blood regulatory element enrichment
analysis of the response DMCs with p value < 1e−3 and p value < 1e−4. Fisher test: *: p value < 0.01. B–D Functional enrichment analysis of the
response DMCs. Enrichment of functional grouping of genes through the biological process, groups of the genes in the same pathway through
KEGG, pathway interaction database as well as the WikiPathways, and the similar domain and features of the gene’s product proteins through PFAM
and Interpro domain database were illustrated in (B), (C) and (D), respectively. The number of genes in each item and p value of the enrichment
analysis was shown in the legend

enrichment was not significant (p value = 0.15) due to
the small number of overlapped CpGs being counted.
Interestingly, one response DMC (with p value = 1e−5)
at chr11:68608981, which is located within the CTP1A
gene, was within 200 bp to the reported GH DMC at
chr11:68609166 (p value = 1e−5, [32]).
It was reported that the effect of GH treatment on
growth is potentially influenced by individual’s SNPs
[33]. We first linked our response DMCs to 37 potential SNPs which were reported to be GH-response-associated SNPs. We observed that only 14 SNPs have their
surrounding CpGs in our tested CpG sets within 5 kb
distance. Interestingly, three of these 14 potential SNPs
were showing significant response DMCs (p value < 0.01)
within a 5 kb distance to these SNPs. Particularly, one
SNP (rs6600230, chr16:738477) is overlapping with
the gene WDR24 where multiple CpGs were showing
p value < 0.05 with the significant one (chr16:739598)
located at the first exon region (p value = 0.01).

Discussion
The emerging field of pharmacoepigenomics will provide
promising insights into the role drugs play in modulating
the host epigenome and in addressing inter-individual
variability in drug response and adverse effects. Although
there is growing evidence that pharmacoepigenetics has

the potential to become an important element of personalized medicine, we know of no study that has evaluated the changes in the individual methylome of the same
group of patients undergoing a treatment, as performed
in the current study. An additional advantage of our
pharmacoepigenetic study is that clinical (growth rate,
height) and biological outcomes (IGF1) can be quantified in response to precise rhGH dosing carefully injected
by parents. More specifically, our data provide the first
comprehensive pharmacoepigenomics analysis on rhGH
treatment in children with ISS by comparing DNA methylation marks before and after several months of rhGH
treatment. We identified 267 response DMCs which are
associated with 265 genes and these genes were enriched
in the biological process of cell differentiation, system
development and different growth-related pathways such
as endoderm differentiation, adipocytokine signaling,
PPAR alpha and TGF-beta signaling pathways. This pilot
study thus supports the existence of dynamic epigenetic
changes in response to rhGH treatment. Again, it should
be recalled that these are methylation changes induced
by prolonged GH administration, and not epigenetic
marks associated with short stature, an example of which
can be found in one of our previous studies [34].
Our customized methylation sequencing panel captured more than 5 million CpGs, which is much larger
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than the previously used 450 K array data (i.e., > 10 folder
larger), representing an unprecedented level of resolution. After quality control, more than 3.3 million CpGs
remained for the response association analysis, providing
the potential to discover novel signals. Indeed, of identified 267 response DMCs (with p value < 1e−4), only 114
(43%) of them are located within 100 bp distance to the
known 450 K loci and only 25 (9.4%) of them are exactly
located at the 450 K loci. Among the top 20 response
DMCs listed in Table 2, half of them does not have neighboring CpGs (with 100 bp distance) in 450 K loci.
Previous studies had shown that the TGF-beta signaling pathway plays an important role in regulating
osteoblast differentiation and could inhabit IGF-1/Akt
signaling pathway [35]. The adipocytokine pathway and
cAMP-signaling pathway are downstream signaling pathways upon activation of IGF1 receptor and contribute to
the signal transduction of insulin-like growth factors on
growth [36]. Another study reported that the GH modulates EGFR expression and signaling and further activates
PI3K-Akt signaling, which was enriched in our response
DMCs (p value < 1e−3) [37]. Moreover, our response
DMC-associated genes were enriched in DNA-binding
transcription factors as well as proteins with the common
domain families of “WH/WH-like DNA” and “TIMP.”
Particularly, TIMP3 is known to modulate GHR abundance and GH sensitivity [38], and NFKB1 is a known
gene associated with short stature [39] and the growthpromoting effects of the transcription factor family of
NFKB seems to be facilitated by GH and IGF-1[40], while
FOXA1, FOXN1 are regulators for GH activation [41].
Here, our identified genes with rhGH-associated methylation changes were enriched in these pathways, supporting the biological relevance of our findings. The genes
involved in these pathways include CDKN2B, LEFTY2,
PPP2R1B, CPT1A, RXRA, NFKB1, KCNMA1, BORCS8MEF2B, MRVI1, PPIF and GATA4 (See the full response
DMC list at p value < 1e−3, Additional file 1: Table S4).
The current study identified marked intra-individual
responses of DNA-methylation to long-term rhGH treatment. A study by Kolarova et al. investigated 24 patients
at baseline and after only 4 days of rhGH administration [32]. The studied patients had various forms of GH
deficiency (N = 13) or other pathological conditions,
which could influence the epigenetic responses to rhGH
and complicate the interpretation. In comparison, only
healthy children were selected for the current study and
were either prepubertal or with minimal manifestations
of puberty in order to avoid epigenetic changes that are
associated in blood cells with advancing puberty [42].
Array-based DNA-methylation profiling of paired
peripheral blood mononuclear cell samples in the
Kolarova et al.’s study revealed clustering according
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to individuals rather than treatment [32]. Supervised
analysis identified 239 CpGs as significantly differentially methylated between baseline and acutely GHstimulated samples, which nevertheless did not retain
significance after adjustment for multivariate analysis.
In a companion study, Kolarova et al. investigated the
long-term effects of prolonged rhGH treatment on the
DNA-methylome and analyzed peripheral blood cells
from an independent cohort of 36 rhGH-treated children born small for gestational age (SGA) compared
to 18 untreated controls. These were not paired samples which had to face major unwanted inter-individual variance of children methylome. No differentially
methylated targets reached the level of significance in
this long-term rhGH-treated cohort [32]. Our study
did not replicate any of these 239 DMCs but observed
a slight enrichment if considering significant response
DMCs in 1 kb distance to them. The lack of high replicates might due to different etiologies of short stature
(intrauterine growth retardation may influence epigenetic marks in the Kolarova et al.’s study) design, different treatment durations and dosing, different ages and
more importantly the considerable inter-individual heterogeneity, while our study investigated paired intraindividual changes in methylation.
Of interest, MEX3C, the top gene in our response
association analysis, was reported to be a translational
regulator of IGF expression in mice [43]. IGF1 protein
expression in bone cells was decreased upon MEX3C
deficiency in Mex3c homozygous mutant mice. Given
that MEX3C is highly conserved among mammalian
species, the observation in mice might be relevant to
the human IGF1 regulation and warrants further investigation. Among the top 20 signals, the response DMC
at CPT1A (chr11:68608981) was close to the reported
locus (cg20228509, chr11:68609166) within 1 kb in the
Kolarova et al.’s short-term rhGH treatment study [32].
CPT1A was observed to be a genetic regulation of fatty
acid metabolism, and missense mutation reduces height
[44]. Although this evidence was not revealed in epigenetic studies, the potential pathway CPT1A involved
(such as the adipocytokine signaling pathway, an important pathway related to IGF signaling) might indicate its
indirect association with GH. In the same study, more
than 3 CpGs in SLC15A4 were identified as differentially
methylated loci and two of them were further validated
with bisulfite pyrosequencing [32]. Our data showed the
top signal was at the downstream of SLC15A4, and a few
CpGs with nominal significance at p value < 0.01 were
located in the intron of SLC15A4 gene. In addition, we
also observed a couple of non-coding RNAs at our top
signals list. Their functions related to GH are currently
unknown and need further exploration.
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As in almost all epigenetic studies in humans, we were
only able to characterize DNA methylation in blood cells,
which may not recapitulate all GH-induced changes that
may occur in other target cells. However, PBMC are sensitive to the GH/IGF1 axis [45] and may thus reveal epigenetic changes triggered by GH or IGF1. B-lymphocytes
and monocytes as well as T-lymphocytes and natural
killer cells express GH receptors on their cell surfaces [46,
47]. These cells also express IGF1 receptors [48], which
activate the mTOR pathway and can subsequently induce
epigenomic changes [49]. GH [50–52] and IGF1 signaling
[53, 54] have been studied in PBMC and lymphocytes.
Since the top variable CpGs in our study were highly
associated with the proportion changes of T cell and
neutrophils, we applied a well-established computational
approach to deconvolute the PBMC blood compositions
and included them as covariates in our analysis model,
which would effectively remove the confounders due to
dynamic blood cell proportion changes. Finally, the current study supports the utility of PBMC to detect DNA
methylation changes responding to rhGH treatment.
In summary, we have identified multiple response
DMCs that are associated with rhGH treatment although
none of them show the FDR significance after multiple
testing correction. This is most likely due to the limited
sample size given the large inter-individual variation in
DNA methylation changes, which restricted our power to
detect significant associations at FDR q-value threshold
of 0.05. The downstream functional analysis revealed that
the response DMCs were enriched in many pathways
biologically relevant to GH. Larger sample sizes will be
needed to more definitively identify epigenetic changes
arising from rhGH administration. Further functional
genomics investigations are also encouraged for validation of our discoveries, particularly for the top signals.
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